Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Deployment of in silico and in vitro Safety Assays in Early-Stage Drug Discovery

Published: Friday, July 20, 2012
Last Updated: Friday, July 20, 2012
Bookmark and Share
This article discusses the use of in silico and cell-based assays in de-risking compounds in the early chemistry space.

One of the main reasons for the cost explosion in drug development is the increase in attrition, especially in highly expensive later-stage clinical trials. Between 1990 and 2004, attrition increased to 70% in Phase II and 50% in Phase III, and it is estimated that of all compounds that make it into the clinic, only 11% reach the market. Some of these later stage failures can be explained by a few factors: a shift in market potential; targets in a more complex biological context and lack of efficacy; and the need for new drugs with better efficacy or safety profile than the current standard of care. Toxicity, however, is the main reason for attrition, accounting for 30% of compound failure in clinical trials and 40–60% failure in preclinical work.

As such, the pharmaceutical industry is greatly interested in reducing costly late-stage attrition by shifting compound failure earlier in the R&D pipeline and, if possible, even before preclinical in vivo studies. In fact, the National Research Council in its 2007 report “Toxicity Testing in the 21st Century: A Vision and a Strategy” calls for transforming toxicology “from a system based on whole-animal testing to one founded primarily on in vitro methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin.” And indeed, using in vitro assays to assess compound-induced toxicity has a long history dating back more than half a century; for example, the use of cells to measure the toxicity of sulphonamide drugs was published in 1941.

The full article is published online in Future Medicinal Chemistry and is free to access.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Applying Deep Learning to Drug Discovery
Researchers train deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
Making Genetic Data Easier to Search
Scripps team streamlines biomedical research by making genetic data easier to search.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!